Key Takeaways
- Crop genomics funding has transitioned from large-scale platform rounds to targeted, niche-focused investments in specific biological outcomes.
- Recent seed and Series A rounds — such as Biographica's £7M and Resurrect Bio's $8.1M — reflect investors targeting disease resistance and AI-driven gene discovery.
- Pairwise's Fulcrum® platform has shifted from proprietary asset to a widely licensed industry tool, signalling CRISPR's transition to standardised infrastructure.
- The geographic scope of crop genomics investment has expanded significantly beyond the U.S. Corn Belt into Europe, Asia, and sub-Saharan Africa.
- The dominant news type in the sector has shifted from R&D announcements to commercial approvals, signalling industry-wide maturation.
The End of the Platform Era
Between 2014 and 2022, the defining investment logic in crop genomics was the platform play. Firms raised capital on the promise of foundational tools — AI-driven breeding systems, CRISPR genomic libraries, biological input platforms — and valuations reflected the breadth of what those tools might eventually address. The largest rounds were correspondingly large: Indigo Ag's $100 million Series C in 2016, Inari's $200 million Series D in 2021, and a succession of nine-figure raises for companies whose primary asset was their methodology.
That era has closed. The data from 2025 and 2026 shows a materially different pattern in crop genomics funding. The dominant investment structure is now smaller, more targeted, and oriented toward specific biological outcomes rather than generalised platforms.
Crop Genomics Funding in 2025–2026: What the Data Shows
The Precision Funding Pattern
Two recent entries illustrate the new investment logic. Biographica closed a £7 million seed round, with the capital directed specifically toward AI-driven gene discovery for disease resistance — a defined problem with a defined target market. Resurrect Bio raised $8.1 million in a Series A focused on a similarly bounded objective.
